Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 29;28(11):4413.
doi: 10.3390/molecules28114413.

Chronic Inflammation's Transformation to Cancer: A Nanotherapeutic Paradigm

Affiliations
Review

Chronic Inflammation's Transformation to Cancer: A Nanotherapeutic Paradigm

Sayed Sartaj Sohrab et al. Molecules. .

Abstract

The body's normal immune response against any invading pathogen that causes infection in the body results in inflammation. The sudden transformation in inflammation leads to the rise of inflammatory diseases such as chronic inflammatory bowel disease, autoimmune disorders, and colorectal cancer (different types of cancer develop at the site of chronic infection and inflammation). Inflammation results in two ways: short-term inflammation i.e., non-specific, involves the action of various immune cells; the other results in long-term reactions lasting for months or years. It is specific and causes angiogenesis, fibrosis, tissue destruction, and cancer progression at the site of inflammation. Cancer progression relies on the interaction between the host microenvironment and tumor cells along with the inflammatory responses, fibroblast, and vascular cells. The two pathways that have been identified connecting inflammation and cancer are the extrinsic and intrinsic pathways. Both have their own specific role in linking inflammation to cancer, involving various transcription factors such as Nuclear factor kappa B, Activator of transcription, Single transducer, and Hypoxia-inducible factor, which in turn regulates the inflammatory responses via Soluble mediators cytokines (such as Interleukin-6, Hematopoietin-1/Erythropoietin, and tumor necrosis factor), chemokines (such as Cyclooxygenase-2, C-X-C Motif chemokines ligand-8, and IL-8), inflammatory cells, cellular components (such as suppressor cells derived from myeloid, tumor-associated macrophage, and acidophils), and promotes tumorigenesis. The treatment of these chronic inflammatory diseases is challenging and needs early detection and diagnosis. Nanotechnology is a booming field nowadays for its rapid action and easy penetration inside the infected destined cells. Nanoparticles are widely classified into different categories based on their different factors and properties such as size, shape, cytotoxicity, and others. Nanoparticles emerged as excellent with highly progressive medical inventions to cure diseases such as cancer, inflammatory diseases, and others. Nanoparticles have shown higher binding capacity with the biomolecules in inflammation reduction and lowers the oxidative stress inside tissue/cells. In this review, we have overall discussed inflammatory pathways that link inflammation to cancer, major inflammatory diseases, and the potent action of nanoparticles in chronic inflammation-related diseases.

Keywords: cancer; drug delivery; inflammation; inflammatory pathways; nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

Figure 1
Figure 1
The cascades of inflammatory pathways leading to the onset of cancer, Protein inhibitor of activated STAT (PIAS), NF-kβ (Nuclear Factor Kappa β), IKB (Inhibitor of Nuclear Factor Kappa β), JAK (Janus Kinase), and TYK2 (Tyrosine Kinase).
Figure 2
Figure 2
Physiochemical attributes of a drug delivery carrier to consider and improve the therapeutic ability of the drug-loaded drug delivery systems.

Similar articles

Cited by

References

    1. Gansler T., Ganz P.A., Grant M., Greene F.L., Johnstone P., Mahoney M., Newman L.A., Oh W.K., Thomas C.R., Jr., Thun M.J. Sixty Years of CA: A Cancer Journal for Clinicians. CA A Cancer J. Clin. 2010;60:345–350. doi: 10.3322/caac.20088. - DOI - PubMed
    1. Balkwill F., Mantovani A. Inflammation and Cancer: Back to Virchow? Lancet. 2001;357:539–545. doi: 10.1016/S0140-6736(00)04046-0. - DOI - PubMed
    1. Chen L., Deng H., Cui H., Fang J., Zuo Z., Deng J., Li Y., Wang X., Zhao L. Inflammatory Responses and Inflammation-Associated Diseases in Organs. Oncotarget. 2018;9:7204–7218. doi: 10.18632/oncotarget.23208. - DOI - PMC - PubMed
    1. Greten F.R., Grivennikov S.I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27–41. doi: 10.1016/j.immuni.2019.06.025. - DOI - PMC - PubMed
    1. Balkwill F.R., Mantovani A. Cancer-Related Inflammation: Common Themes and Therapeutic Opportunities. Volume 22. Elsevier; Amsterdam, The Netherlands: 2012. pp. 33–40. - PubMed